CRISP3 and prostate carcinoma: Asmann et al. [30], using publicly available whole-genome expression data from normal and malignant prostate samples, and Ernst et al. [31], comparing 12,600 transcripts in 9 normal and 17 malignant prostate tissues, independently reported a significant overexpression of CRISP3 in prostate carcinomas, being subsequently suggested as a potential prostate cancer specific biomarker [32], [33], [34].